TY - JOUR
T1 - The Proteolytic Landscape of Ovarian Cancer
T2 - Applications in Nanomedicine
AU - O’Connell, Cailin
AU - VandenHeuvel, Sabrina
AU - Kamat, Aparna
AU - Raghavan, Shreya
AU - Godin, Biana
N1 - Funding Information:
C.O. acknowledges kind support from the Brown, Smith & Raymond EnMed Capstone Innovator Award, and is a Burroughs Wellcome Fund Scholar supported by a Burroughs Wellcome Fund Physician Scientist Institutional Award to the Texas A&M University Academy of Physician Scientists. A.K., S.R. and B.G. acknowledge generous support from the Houston Methodist Cancer Center. B.G. acknowledges kind support from the Department of Defense/US Army Medical Research Grant W81XWH2110012. S.R. acknowledges Texas A&M Triads for Transformation.
Publisher Copyright:
© 2022 by the authors.
PY - 2022/9/1
Y1 - 2022/9/1
N2 - Ovarian cancer (OvCa) is one of the leading causes of mortality globally with an overall 5-year survival of 47%. The predominant subtype of OvCa is epithelial carcinoma, which can be highly aggressive. This review launches with a summary of the clinical features of OvCa, including staging and current techniques for diagnosis and therapy. Further, the important role of proteases in OvCa progression and dissemination is described. Proteases contribute to tumor angiogenesis, remodeling of extracellular matrix, migration and invasion, major processes in OvCa pathology. Multiple proteases, such as metalloproteinases, trypsin, cathepsin and others, are overexpressed in the tumor tissue. Presence of these catabolic enzymes in OvCa tissue can be exploited for improving early diagnosis and therapeutic options in advanced cases. Nanomedicine, being on the interface of molecular and cellular scales, can be designed to be activated by proteases in the OvCa microenvironment. Various types of protease-enabled nanomedicines are described and the studies that focus on their diagnostic, therapeutic and theranostic potential are reviewed.
AB - Ovarian cancer (OvCa) is one of the leading causes of mortality globally with an overall 5-year survival of 47%. The predominant subtype of OvCa is epithelial carcinoma, which can be highly aggressive. This review launches with a summary of the clinical features of OvCa, including staging and current techniques for diagnosis and therapy. Further, the important role of proteases in OvCa progression and dissemination is described. Proteases contribute to tumor angiogenesis, remodeling of extracellular matrix, migration and invasion, major processes in OvCa pathology. Multiple proteases, such as metalloproteinases, trypsin, cathepsin and others, are overexpressed in the tumor tissue. Presence of these catabolic enzymes in OvCa tissue can be exploited for improving early diagnosis and therapeutic options in advanced cases. Nanomedicine, being on the interface of molecular and cellular scales, can be designed to be activated by proteases in the OvCa microenvironment. Various types of protease-enabled nanomedicines are described and the studies that focus on their diagnostic, therapeutic and theranostic potential are reviewed.
KW - cathepsin
KW - kallikrein
KW - matrix metalloproteinase
KW - nanomedicine
KW - nanoparticle
KW - ovarian cancer
KW - protease
KW - trypsin
KW - urokinase plasminogen activator
KW - Humans
KW - Tumor Microenvironment
KW - Ovarian Neoplasms/diagnosis
KW - Carcinoma, Ovarian Epithelial
KW - Female
KW - Endopeptidases
KW - Nanomedicine
UR - http://www.scopus.com/inward/record.url?scp=85137588251&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137588251&partnerID=8YFLogxK
U2 - 10.3390/ijms23179981
DO - 10.3390/ijms23179981
M3 - Review article
C2 - 36077371
AN - SCOPUS:85137588251
SN - 1661-6596
VL - 23
JO - International journal of molecular sciences
JF - International journal of molecular sciences
IS - 17
M1 - 9981
ER -